ClinicalTrials.gov record
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

ClinicalTrials.gov ID: NCT06772623

Public ClinicalTrials.gov record NCT06772623. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations

Study identification

NCT ID
NCT06772623
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
AbbVie
Industry
Enrollment
252 participants

Conditions and interventions

Conditions

Not listed

Interventions

Not listed

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 5, 2025
Primary completion
Oct 31, 2027
Completion
Oct 31, 2027
Last update posted
Feb 26, 2026

2025 – 2027

United States locations

U.S. sites
19
U.S. states
13
U.S. cities
19
Facility City State ZIP Site status
Providence - St. Jude Medical Center /ID# 271414 Fullerton California 92835 Recruiting
FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450 Oxnard California 93030 Recruiting
UCLA - Santa Monica /ID# 271690 Santa Monica California 90404 Recruiting
University Of Colorado - Anschutz Medical Campus /ID# 269069 Aurora Colorado 80045 Recruiting
Rocky Mountain Cancer Centers - Lone Tree /ID# 272603 Lone Tree Colorado 80124 Recruiting
Mid Florida Hematology And Oncology Center /ID# 273777 Orange City Florida 32763 Recruiting
Hope And Healing Cancer Services /ID# 276223 Hinsdale Illinois 60521 Recruiting
Community Health Network /ID# 273437 Indianapolis Indiana 46202 Recruiting
Astera Cancer Care /ID# 271915 East Brunswick New Jersey 08816-4096 Recruiting
New York Cancer And Blood Specialists - Shirley /ID# 272547 Shirley New York 11967 Recruiting
University Hospitals Cleveland Medical Center /ID# 271726 Cleveland Ohio 44106 Recruiting
The Mark H Zangmeister Center /ID# 272502 Columbus Ohio 43219 Recruiting
Spoknwrd Clinical Trials /ID# 273776 Easton Pennsylvania 18045 Recruiting
Millennium Research & Clinical Development /ID# 271717 Houston Texas 77090 Completed
Joe Arrington Cancer Research /ID# 272776 Lubbock Texas 79410-1121 Recruiting
Huntsman Cancer Institute /ID# 271686 Salt Lake City Utah 84112 Recruiting
Virgnia Cancer Specialists /ID# 269633 Leesburg Virginia 20176 Recruiting
Vista Oncology - East Olympia /ID# 275438 Olympia Washington 98506 Recruiting
Northwest Medical Specialties Tacoma /ID# 270469 Tacoma Washington 98405 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06772623, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 26, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06772623 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →